Fed’s Powell opens door to potential rate cuts at Jackson Hole
BRENTWOOD, TN—Marissa Brittenham, the Chief Strategy Officer of Surgery Partners, Inc. (NASDAQ:SGRY), recently sold 3,156 shares of the company’s common stock, according to a filing with the Securities and Exchange Commission. The transaction, which took place on March 10, 2025, was valued at approximately $76,028, with shares sold at an average price of $24.09 each. The sale comes as the $2.98 billion healthcare company shows strong revenue growth of 13.5% over the last twelve months, according to InvestingPro data.
Following this sale, Brittenham retains direct ownership of 63,408 shares in the company. The sale was conducted to satisfy tax withholding obligations related to the vesting of restricted stock earlier in the year. Surgery Partners, Inc., headquartered in Brentwood, Tennessee, operates in the general medical and surgical hospital services sector. InvestingPro analysis indicates the stock is currently undervalued, with analysts setting price targets up to $36. Get access to 7 more exclusive ProTips and comprehensive analysis in the Surgery Partners Pro Research Report, part of our coverage of 1,400+ US stocks.
In other recent news, Surgery Partners Inc . reported fourth-quarter 2024 earnings that exceeded analysts’ expectations, with an EPS of $0.44 compared to the forecasted $0.39. The company also surpassed revenue forecasts, reporting $864.4 million against an anticipated $827.9 million. For the full year, Surgery Partners achieved over $3 billion in revenue and $500 million in adjusted EBITDA, marking significant milestones. Looking ahead, the company projects 2025 net revenue between $3.3 billion and $3.45 billion, with adjusted EBITDA expected to range from $555 million to $565 million.
In terms of analyst actions, Benchmark adjusted the price target for Surgery Partners shares to $35 from $40 while maintaining a Buy rating, following the company’s fourth-quarter results and 2025 guidance. UBS also revised its price target to $34 from $38, maintaining a Buy rating, citing recent divestitures and updated financial projections. KeyBanc, meanwhile, maintained a Sector Weight rating on the company’s stock.
Additionally, Surgery Partners is currently the focus of a nonbinding acquisition proposal from Bain Capital, offering $25.75 per share. This proposal highlights ongoing interest from private equity firms in the healthcare sector. Surgery Partners’ management has expressed confidence in its financial outlook despite potential regulatory changes, emphasizing its strategic positioning and growth potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.